LOGO
LOGO

entertainment news

Why November 27 Matters for This Rare Muscular Dystrophy?

November 03, 2026 10:34 ET
A key date in rare disease research. BridgeBio Pharma’s BBP-418 is under FDA Priority Review for limb-girdle muscular dystrophy type 2I/R9, a rare genetic disease with no approved treatment. The FDA decision is targeted for November 27. If approved, BBP-418 could become the first approved therapy for any form of limb-girdle muscular dystrophy.